Genmab A/S Sponsored ADR (GMAB) vs Royalty Pharma PLC (RPRX)
Genmab A/S Sponsored ADR and Royalty Pharma PLC are both Biotechnology companies. Royalty Pharma PLC is the larger, with a market value of $34.4B against $20.8B — 1.7× the size. Genmab A/S Sponsored ADR trades at the lower P/E: 27.8× against 40.1×. Genmab A/S Sponsored ADR grew revenue faster over the last twelve months: 22.3% against 10.0%. Royalty Pharma PLC has the higher net margin (32.0% vs 19.1%) and the lower return on invested capital (5.28% vs 6.99%). Across the 21 metrics below, Genmab A/S Sponsored ADR leads on 13 and Royalty Pharma PLC on 8.
Valuation
Profitability
| Metric | GMAB | RPRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 93.03% | 100.00% | 65.16% |
| Operating margin | 25.95% | 59.61% | 0.00% |
| Net margin | 19.08% | 32.02% | 0.00% |
| Free cash flow margin | (153.64%) | 51.66% | 0.00% |
| Return on equity | 14.00% | 8.42% | (57.72%) |
| Return on assets | 8.30% | 4.26% | (49.22%) |
| Return on invested capital | 6.99% | 5.28% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack